scholarly journals Quality Management System Program of in Vitro/in Vivo Test Facility of Boron Neutron Capture Therapy at Kartini Research Reactor

2016 ◽  
Vol 1 (2) ◽  
pp. 108
Author(s):  
Widarto Widarto ◽  
Isman Mulyadi Tri Atmoko ◽  
Gede Sutresna Wijaya
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Research Reactor ◽  
Test Facility ◽  
Neutron Capture Therapy ◽  
In Vivo Test ◽  
Boron Neutron Capture ◽  
System Program

The quality manajement system program of in vitro / in vivo test facility of  Boron Neutron Capture Therapy (BNCT) methode as quality assurance requirement for utilization of radial pearcing beamport of Kartini research have been done.  Identification and management of technical specification and parameters meassurement of to the radial piercing beamport have been determined for preparing in vitro / in vivo test facility. The parameters are epithermal neutron flux is  9,8243E+05  n cm<sup>-2</sup> s<sup>-1</sup>and  thermal neutron flux is 3,0691E+06 n cm<sup>-2</sup> s<sup>-1</sup>, radiation shielding of parafin,  dimension and size  of piercing radial and instrumentatin and control system for automatic transfer of in vitro / in vivo samplels have been documented. Management system of the documents for fullfil  basic guidance to perform working job of in vitro / in vivo at the piercing radial beamport of Kartini Research Reactor in order purpose utilization of the reactor  for safety worker of the radiation area, society  and invironment beeing safely

scholarly journals Optimization of Neutron Collimator in The Thermal Column of Kartini Research Reactor for in vitro and in vivo Trials Facility of Boron Neutron Capture Therapy using MCNP-X Simulator

2016 ◽  
Vol 1 (1) ◽  
pp. 54
Author(s):  
Ranti Warfi ◽  
Andang Widi Harto ◽  
Yohannes Sardjono ◽  
Widarto Widarto
Keyword(s):  
Neutron Beam ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Epithermal Neutron ◽  
Research Reactor ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Thermal Column

<span>The optimization of thermal column collimator has been studied which resulted epithermal neutron beam for in vivo and in vitro trials of Boron Neutron Capture Therapy (BNCT) at Kartini Research Reactor of 100 kW by means of </span><em>Monte Carlo N-Particle Extended </em><span>(MCNP-X) codes. The design criteria were based on recommendation from the International Atomic Energy Agency (IAEA). MCNP-X calculations indicated by using 5 cm thickness of Ni as collimator wall, 30 cm thickness of Al as moderator, 20 cm thickness of 60Ni as filter, 2 cm thickness of Bi as γ-ray shielding, 3 cm thickness of 6Li2CO3-polyethylene as beam delimiter, and for in vivo in vitro trials purpose, aperture was designed 8 cm radius size, an epitermal neutron beam with an intensity 1.13E+09 n.cm-2.s-1, fast neutron and γ-doses per epithermal neutron of 1.76E-13 Gy.cm2.n-1 and 1.45E-13Gy.cm2.n-1,minimum thermal neutron per epithermal neutron ratio of 0.008,and maximum directionality of 0.73, respectively could be produced. The results have passed all the IAEA’s criteria.</span>

scholarly journals The Voxel Mice Model of MCNPX for Simulation In Vivo Test BNCT

2016 ◽  
Vol 1 (3) ◽  
pp. 151
Author(s):  
Agung Prastowo ◽  
Yohannes Sardjono ◽  
Widarto Widarto
Keyword(s):  
Monte Carlo ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Simulation Software ◽  
Neutron Capture Therapy ◽  
Mice Model ◽  
In Vivo Test ◽  
Boron Neutron Capture ◽  
Simulation Input

A study of voxel mice model of MCNPX has been done for in vivo test Boron Neutron Capture Therapy (BNCT). Mathematical and parameters were used to construct the stylized Mice model phantom. The geometry was modified into simulation software MCNPX (Monte Carlo N-Particle eXtended) simulation input. The result of mice stylized model phantom has been showed Figure 3.

Functionalized mesoporous silica nanoparticles for innovative boron-neutron capture therapy of resistant cancers

2018 ◽  
Author(s):  
Guillaume Vares ◽  
Vincent Jallet ◽  
Yoshitaka Matsumoto ◽  
Cedric Rentier ◽  
Kentaro Takayama ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Mesoporous Silica Nanoparticles ◽  
Alpha Particles ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

AbstractTreatment resistance, relapse and metastasis remain critical issues in some challenging cancers, such as chondrosarcomas. Boron-neutron Capture Therapy (BNCT) is a targeted radiation therapy modality that relies on the ability of boron atoms to capture low energy neutrons, yielding high linear energy transfer alpha particles. We have developed an innovative boron-delivery system for BNCT, composed of multifunctional fluorescent mesoporous silica nanoparticles (B-MSNs), grafted with an activatable cell penetrating peptide (ACPP) for improved penetration in tumors and with Gadolinium for magnetic resonance imaging (MRI)in vivo. Chondrosarcoma cells were exposedin vitroto an epithermal neutron beam after B-MSNs administration. BNCT beam exposure successfully induced DNA damage and cell death, including in radio-resistant ALDH+ cancer stem cells (CSCs), suggesting that BNCT using this system might be a suitable treatment modality for chondrosarcoma or other hard-to-treat cancers.

scholarly journals Rational Design of Albumin Theranostic Conjugates for Gold Nanoparticles Anticancer Drugs: Where the Seed Meets the Soil?

Biomedicines ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 74
Author(s):  
Tatyana V. Popova ◽  
Inna A. Pyshnaya ◽  
Olga D. Zakharova ◽  
Andrey E. Akulov ◽  
Oleg B. Shevelev ◽  
...  
Keyword(s):  
Gold Nanoparticles ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Rational Design ◽  
Chemotherapeutic Agents ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Theranostic Agents

Multifunctional gold nanoparticles (AuNPs) may serve as a scaffold to integrate diagnostic and therapeutic functions into one theranostic system, thereby simultaneously facilitating diagnosis and therapy and monitoring therapeutic responses. Herein, albumin-AuNP theranostic agents have been obtained by conjugation of an anticancer nucleotide trifluorothymidine (TFT) or a boron-neutron capture therapy drug undecahydro-closo-dodecaborate (B12H12) to bimodal human serum albumin (HSA) followed by reacting of the albumin conjugates with AuNPs. In vitro studies have revealed a stronger cytotoxicity by the AuNPs decorated with the TFT-tagged bimodal HSA than by the boronated albumin conjugates. Despite long circulation time, lack of the significant accumulation in the tumor was observed for the AuNP theranostic conjugates. Our unique labelling strategy allows for monitoring of spatial distribution of the AuNPs theranostic in vivo in real time with high sensitivity, thus reducing the number of animals required for testing and optimizing new nanosystems as chemotherapeutic agents and boron-neutron capture therapy drug candidates.

scholarly journals Preparation of Dosimetry of Boron Neutron Capture Therapy (BNCT) for In vivo Test Planning system using Monte Carlo N-Particle Extended (MCNP-X) Software

2016 ◽  
Vol 1 (2) ◽  
pp. 99
Author(s):  
Muhammad Ilma Muslih Arrozaqi ◽  
Kusminarto Kusminarto ◽  
Yohannes Sardjono
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Flux Ratio ◽  
Planning System ◽  
Neutron Capture Therapy ◽  
In Vivo Test ◽  
Phantom Model ◽  
Boron Neutron Capture ◽  
Neutron Component

Cancer is a disease with second largest patients in the world.  In Indonesia, the number of radiotherapy facility in Indonesia is less than 30 units and every patients needs more than single exposure, so that it result a long waiting list of treatment up to one year. Now, a new treatment of cancer is developed. It is Boron Neutron Capture Therapy that using capture reaction of neutron by Boron-10. Before this method is applied to patient, it requires some testing which is one of them is in vivo test. This research has been conducting to prepare the in vivo test, especially in dosimetry. Preparation of dosimetry includes collimator design and mouse phantom model. The optimum specification of the collimator is consist of Nickel collimator wall with 2 cm of thickness, Aluminum moderator with 10 cm of thickness and lead gamma shield with 3.5 of thickness. This design result in 1.18 x 10<sup>8</sup> n/cm<sup>2</sup>s of epithermal and thermal neutron flux, 2,24 x 10<sup>-11</sup> Gy cm<sup>2</sup>/s of fast neutron component dose, 1.35 x 10<sup>-12</sup> Gy cm<sup>2</sup>/s of gamma dose component, and 7.18 x 10<sup>-1</sup> of neutron current and flux ratio. Mouse phantom model is built by two basic kind of geometry, they are Ellipsoid and Elliptical Tory. Both of basic geometry can be used to make all important organs of mouse phantom for dosimetry purpose.

scholarly journals Biological Shielding Design of In Vitro Test Facility Boron Neutron Capture Therapy (BNCT) at Radial Piercing Beam Port of Kartini Research Reactor Using MCNPX

2016 ◽  
Vol 1 (3) ◽  
pp. 166
Author(s):  
Widarto Widarto ◽  
Buyung Edi Prabowo
Keyword(s):  
Neutron Capture ◽  
Research Reactor ◽  
Test Facility ◽  
Neutron Capture Therapy ◽  
In Vitro Test ◽  
Boron Neutron Capture ◽  
Beam Port ◽  
Vitro Test ◽  
Shielding Design

<p>This research aimed to determine material specification of radiation biological shielding design of neutron and gamma output on radial piercing beamport of Kartini Research Reactor using MCNPX code,  as safety radiation protection purpose of in vitro / in vivo irradiation test facility. Refference input data using parameters of neutron and gamma as result simmulation researcher before  as follows Ф<sub>th</sub> is 5.00 x 10<sup>8 </sup>n.cm<sup>-2</sup>s<sup>-1</sup>, Ф<sub>epi</sub> is 1.23 x 10<sup>8</sup> n.cm<sup>-2</sup>s<sup>-1</sup>, Ф<sub>fast </sub>is 1.35 x 10<sup>9</sup> n.cm<sup>-2</sup>s<sup>-1</sup>, Ḋ<sub>γ</sub> is 2.49 x 10<sup>-3</sup> Sv.s<sup>-1</sup>, Ḋ<sub>n</sub> is 3.63 x 10<sup>-1</sup> Sv.s<sup>-1</sup>. [ Dwi W.]</p>Optimation result of simulation using MCNPX to determine specification material for radiation protection safety are parafin block with thickness  75 cm for neutron shielding  and covered by material lead (Pb) with thickness 15 cm for gamma shieding. By this optimation for the both thickness materials, determination for neutron and gamma dose rate  are as follow , Ḋ<sub>n</sub> = 1,1 x Sv.s<sup>-1</sup> and with Ḋ<sub>γ </sub>= 1,1 x 10<sup>-09 </sup>Sv.s<sup>-1</sup>. Those radiation dose rate of neutron and gamma parameters are still under requirement  of safety dose standard that is 2.78 x 10<sup>-9</sup> Sv.s<sup>-1</sup> as regulation of Regulatory Body BAPETEN. [Perka BAPETEN No. 4 Tahun 2014]. It can be concluded that by the Biological Shielding Design of In Vitro Test Facility Boron Neutron Capture Therapy (BNCT)<em> </em>at Radial Piercing Beam Port of Kartini Research Reactor Using MCNPX can operated safely.

scholarly journals Dosimetry of in vitro and in vivo Trials in Thermal Column Kartini Reactor for Boron Neutron Capture Therapy (BNCT) facility by using MCNPX Simulator Code

2016 ◽  
Vol 1 (2) ◽  
pp. 63
Author(s):  
Adrian Tesalonika ◽  
Andang Widi Harto ◽  
Yohannes Sardjono ◽  
Isman Mulyadi Triatmoko
Keyword(s):  
Dose Rate ◽  
Exposure Time ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Thermal Column ◽  
Tissue Material

<span>A dosimetry study of in vitro and in vivo trials system in thermal column of Kartini Reactor for Boron Neutron Capture Therapy (BNCT) facility has been conducted by using the Monte Carlo N-Particle Extended (MCNPX) software. Source of neutron originated from the 100 kW reactor which has been modified by the previous researcher. Models have been made by using simple geometries to represent tissues. Models of in vitro have been made by 4 spheres each has 1 cm diameter to represent tumour, whereas in vivo by 4 cylinders each has 6 cm length, 3 cm diameter, and breast soft tissue material with 1 cm sphere each located in the center of the cylinders to represent models of mouse with tumour. An increase in value of the boron concentration will increase the value of dose rate as well, then the exposure time should be shorter. The exposure times (in minutes) of in vitro trials for 20, 25, 30, 50, 75, 100, 125, and 150 μg boron/g tissues are 117.77, 117.77, 117.07, 115.69, 114.02, 112.39, 110.80, and 109.27. Whereas the exposure times of in vivo trials are 163.58, 162.78, 161.98, 158.88, 155.16, 151.61, 148.22, dan 144.98. In vitro trials have greater values of dose rate so that in vitro trials have shorter exposure time.</span>

S133 – Boron Neutron Capture Therapy for Melanoma in Nasal Cavity

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P121-P121
Author(s):  
Norimasa Morita ◽  
Aihara Teruhito ◽  
Msako Uno ◽  
Koji Ono ◽  
Tamotsu Harada
Keyword(s):  
Nasal Cavity ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Research Reactor ◽  
Ethics Committees ◽  
Lethal Effect ◽  
Complete Response ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Promising Treatment

Objectives Boron neutron capture therapy (BNCT) is one of the radiation therapies known to have a selective lethal effect on tumor cells. Thermal neutrons are captured by the 10B atom, resulting in the emission of linear recoiling Alfa particles and 7Li nuclei, with traveling ranges of ∼9 and ∼5 micrometers respectively. These particles are high linear energy transfer (LET) radiation and lethally damage DNA. BNCT for cutaneous melanoma, using 10B-para-boronophe-nylalanine (BPA) as the boron delivery agent, was developed and successful BNCT treatment of 18 melanoma patients has been reported by Mishima et al. Methods Based on their treatment regimen and with the approval of the Nuclear Safety Bureau of the Japanese government and the Medical Ethics Committees of Kawasaki Medical School and Kyoto University, we have conducted BNCT clinical trials on patients with mucosal melanomas in head-and-neck at the Kyoto University Research Reactor (KUR) and the Japan Research Reactor No. 4 (JRR-4) since 2005. Results To date, we have treated 6 patients with mucosal melanomas in the nasal cavity with BNCT. 4 patients showed a complete response (CR) by 6 months and 2 patients showed a partial response (PR) 3 months after BNCT. None of the patients showed any serious damage in normal tissue surrounding tumor site. One patient from this study died due to distant metastasis. However, no local recurrence of melanoma has been observed in all CR patients and no regrowth of melanoma in all PR patients. Conclusions BNCT thus is a promising treatment for achieving local control of mucosal melanomas.

Sign in / Sign up

Export Citation Format

Share Document